Clinical Roadmap

Built for the hardest cases.
Expanding to every patient.

LeptonX begins where clinical complexity is highest — rare cancers with ambiguous diagnoses, thin literature, and patients who need clarity most. From there, the platform scales systematically across oncology and beyond.

Phase 2b Complete 96.6% Mean Accuracy Patent Filed Mar 2026
96.6% Mean accuracy · Phase 2b
36 Clinical query dimensions
12 Specialties evaluated

Benchmarked across IHC, molecular, treatment, imaging, recency, and outcomes dimensions. U.S. Provisional Patent filed March 2026.

Now · Active

Rare & Complex Oncology

SarcomaSense® demonstrates that LeptonX's retrieval architecture performs at clinical-grade accuracy on the most demanding oncology use case — rare sarcomas with sparse literature, complex molecular profiles, and high diagnostic ambiguity. If it works here, it works everywhere.

Soft Tissue Sarcoma Bone Sarcoma Retroperitoneal Sarcoma GIST Desmoid Tumors Ewing Sarcoma
Near-Term · In Development

High-Volume Oncology Specialties

The retrieval architecture, IHC handling, molecular testing patterns, and treatment history structures built for sarcoma transfer directly across oncology. Each additional specialty requires a fraction of the original development cost — this is a platform, not a point solution.

Breast Oncology Lung Oncology Gastrointestinal Oncology Hematologic Malignancies Neuro-Oncology Genitourinary Oncology Gynecologic Oncology Head & Neck Oncology
Horizon · Planned

Oncology Platform → Adjacent High-Acuity Specialties

Once the oncology platform is established, the same sovereign AI architecture — patient-owned data, local inference, retrieval-augmented clinical intelligence — extends to any specialty defined by complex multi-system documentation and high interpretive demand.

🫀
Cardiology
Complex multi-system records, imaging interpretation, and chronic disease management across high patient volumes.
🧠
Neurology
Longitudinal disease tracking, genetic testing integration, and rare neurological condition navigation.
🦠
Rare Disease
Ultra-rare conditions where patients are often more informed than their local providers. LeptonX levels that asymmetry.
🏥
Broad Health Intelligence
LPX-EVAL as a published evaluation standard. Patient-sovereign infrastructure as the foundation for responsible health intelligence.

The architecture scales.
The opportunity does too.

Every oncology subspecialty, every rare disease, every high-acuity domain where patients face documentation complexity represents an addressable market. LeptonX's platform approach means each new specialty unlocks TAM at decreasing marginal cost.

~18M
U.S. cancer patients
100+
Oncology subspecialties